sab biotherapeutics, inc. (SABS)

Shares of SAB BIO (SABS), a clinical-stage biopharmaceutical company, touched a new 52-week high of $6.60 in early trading today, following the announcement of an oversubscribed $175 million private placement.

Shares of SAB Biotherapeutics, Inc. (SABS) soared 82% to $4.69 on Thursday following the announcement of a $175 million private placement backed by leading institutional and strategic investors, including Sanofi, RA Capital Management, and Commodore Capital. The stock opened at $3.49, up from the...

SAB Biotherapeutics Inc. (SABS), a clinical-stage biopharmaceutical company, on Tuesday announced positive topline data from its Phase 1 trial of SAB-142, a potential disease-modifying therapy for Type 1 Diabetes. The trial, conducted among healthy volunteers, met its primary objectives related to...

SAB Biotherapeutics, Inc. (SABS), a clinical-stage biopharmaceutical company, has made significant progress with its lead immunotherapy candidate, SAB-142, in the treatment of Type 1 Diabetes (T1D). SAB-142, a human anti-thymocyte immunoglobulin (hIgG), is being developed as a disease-modifying treatment...

SAB Biotherapeutics, Inc. (SABS) announced on Tuesday that the FDA has granted clearance for an investigational new drug application to advance its phase 1 clinical trial of SAB-142 for treating type-1 diabetes. Phase 1 trial of SAB-142 involves a human trial, to evaluate the safety, tolerability,...